A Study Of Maraviroc In HIV Co-Infected Subjects With Hepatitis C And/Or Hepatitis B - Full Text View

Purpose

To describe liver enzyme elevations in patients who are coinfected with HIV and either Hepatitis C (HCV) and/or Hepatitis B (HBV) receiving maraviroc or placebo in combination with their current suppressive anti-HIV drug therapy.

Condition	Intervention	Phase
HIV Coinfection Hepatitis C Hepatitis B Hepatotoxicity	Drug: Maraviroc Drug: Placebo	Phase 4

Study Type:	Interventional
Study Design:	Allocation: Randomized Endpoint Classification: Safety Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Investigator) Primary Purpose: Treatment
Official Title:	A Multicenter, Randomized, Blinded, Placebo-Controlled Study To Evaluate The Safety Of Maraviroc In Combination With Other Antiretroviral Agents In HIV-1-Infected Subjects Co-Infected With Hepatitis C And/Or Hepatitis B Virus

Resource links provided by NLM:

MedlinePlus related topics: HIV/AIDS Hepatitis Hepatitis A Hepatitis B Hepatitis C

Drug Information available for: Maraviroc Hepatitis A Vaccines

U.S. FDA Resources

Further study details as provided by ViiV Healthcare:

Primary Outcome Measures:

Percentage of subjects with Grade 3 and Grade 4 ALT abnormalities. [ Time Frame: 48 weeks ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:

Percentage of subjects with Grade 3 and Grade 4 ALT abnormalities [ Time Frame: 96 weeks ] [ Designated as safety issue: Yes ]
Percentage of subjects with Grade 3 and Grade 4 ALT abnormalities [ Time Frame: 144 weeks ] [ Designated as safety issue: Yes ]
Time to development of Grade 3 and Grade 4 ALT abnormalities [ Time Frame: 48 weeks ] [ Designated as safety issue: Yes ]
Time to development of Grade 3 and Grade 4 ALT abnormalities [ Time Frame: 96 weeks ] [ Designated as safety issue: Yes ]
Time to development of Grade 3 and Grade 4 ALT abnormalities [ Time Frame: 144 weeks ] [ Designated as safety issue: Yes ]
Percentage of subjects with Grade 3 and Grade 4 ALT abnormalities associated with a change from baseline ALT >=100 IU/L [ Time Frame: 48 weeks ] [ Designated as safety issue: Yes ]
Percentage of subjects with Grade 3 and Grade 4 ALT abnormalities associated with a change from baseline ALT >=100 IU/L [ Time Frame: 96 weeks ] [ Designated as safety issue: Yes ]
Percentage of subjects with Grade 3 and Grade 4 ALT abnormalities associated with a change from baseline ALT >=100 IU/L [ Time Frame: 144 weeks ] [ Designated as safety issue: Yes ]
Time to development of Grade 3 and Grade 4 ALT test abnormalities associated with a change from baseline ALT >=100 IU/L [ Time Frame: 48 weeks ] [ Designated as safety issue: Yes ]
Time to development of Grade 3 and Grade 4 ALT test abnormalities associated with a change from baseline ALT >=100 IU/L [ Time Frame: 96 weeks ] [ Designated as safety issue: Yes ]
Time to development of Grade 3 and Grade 4 ALT test abnormalities associated with a change from baseline ALT >=100 IU/L [ Time Frame: 144 weeks ] [ Designated as safety issue: Yes ]
Percentage of subjects with Hy's law abnormalities [ Time Frame: 48 weeks ] [ Designated as safety issue: Yes ]
Percentage of subjects with Hy's law abnormalities [ Time Frame: 96 weeks ] [ Designated as safety issue: Yes ]
Percentage of subjects with Hy's law abnormalities [ Time Frame: 144 weeks ] [ Designated as safety issue: Yes ]
Percentage of subjects with plasma HIV-1 RNA concentration <40 copies/mL [ Time Frame: 48 weeks ] [ Designated as safety issue: Yes ]
Percentage of subjects with plasma HIV-1 RNA concentration <40 copies/mL [ Time Frame: 96 weeks ] [ Designated as safety issue: Yes ]
Percentage of subjects with plasma HIV-1 RNA concentration <40 copies/mL [ Time Frame: 144 weeks ] [ Designated as safety issue: Yes ]
Change from baseline in CD4+ and CD8+ cell counts [ Time Frame: 48 weeks ] [ Designated as safety issue: Yes ]
Change from baseline in CD4+ and CD8+ cell counts [ Time Frame: 96 weeks ] [ Designated as safety issue: Yes ]
Change from baseline in CD4+ and CD8+ cell counts [ Time Frame: 144 weeks ] [ Designated as safety issue: Yes ]
Frequency and severity of adverse events and laboratory abnormalities [ Time Frame: 144 weeks ] [ Designated as safety issue: Yes ]
Change from baseline in markers of immune activation (CD38 expression on CD4 and CD8 cells, C-reactive protein, D-dimer, transforming growth factor-beta [TGF-beta]) [ Time Frame: 48 weeks ] [ Designated as safety issue: No ]
Change from baseline in markers of immune activation (CD38 expression on CD4 and CD8 cells, C-reactive protein, D-dimer, transforming growth factor-beta [TGF-beta]) [ Time Frame: 96 weeks ] [ Designated as safety issue: No ]
Change from baseline in markers of immune activation (CD38 expression on CD4 and CD8 cells, C-reactive protein, D-dimer, transforming growth factor-beta [TGF-beta]) [ Time Frame: 144 weeks ] [ Designated as safety issue: No ]
Change from baseline in plasma HCV RNA [ Time Frame: 48 weeks ] [ Designated as safety issue: No ]
Change from baseline in plasma HCV RNA [ Time Frame: 96 weeks ] [ Designated as safety issue: No ]
Change from baseline in plasma HCV RNA [ Time Frame: 144 weeks ] [ Designated as safety issue: No ]
Change from baseline in plasma HBV DNA [ Time Frame: 48 weeks ] [ Designated as safety issue: No ]
Change from baseline in plasma HBV DNA [ Time Frame: 96 weeks ] [ Designated as safety issue: No ]
Change from baseline in plasma HBV DNA [ Time Frame: 144 weeks ] [ Designated as safety issue: No ]
Change from baseline in Enhanced Liver Fibrosis (ELF) test [ Time Frame: 48 weeks ] [ Designated as safety issue: No ]
Change from baseline in Enhanced Liver Fibrosis (ELF) test [ Time Frame: 96 weeks ] [ Designated as safety issue: No ]
Change from baseline in Enhanced Liver Fibrosis (ELF) test [ Time Frame: 144 weeks ] [ Designated as safety issue: No ]
Change from baseline in the hepatic elastography (FibroscanTM) [ Time Frame: 48 weeks ] [ Designated as safety issue: No ]
Change from baseline in the hepatic elastography (FibroscanTM) [ Time Frame: 96 weeks ] [ Designated as safety issue: No ]
Change from baseline in the hepatic elastography (FibroscanTM) [ Time Frame: 144 weeks ] [ Designated as safety issue: No ]
Change from baseline in fibrosis score (Ishak) in liver biopsy samples at Week 144 (liver biopsy substudy) [ Time Frame: 144 weeks ] [ Designated as safety issue: No ]
Population pharmacokinetic analysis of time versus plasma concentration of maraviroc. [ Time Frame: 48 weeks ] [ Designated as safety issue: No ]
Exploratory exposure-response relationship, if any, between maraviroc PK and liver fibrosis biomarkers, any changes from baseline that may be observed in AST and ALT measurements or other laboratory measurements. [ Time Frame: 48 weeks ] [ Designated as safety issue: No ]
Health economic impact, as measured by the utilization of hepatic fibrosis and cirrhosis-related inpatient and outpatient services and associated costs of care. [ Time Frame: 144 weeks ] [ Designated as safety issue: No ]

Estimated Enrollment:	120
Study Start Date:	April 2011
Estimated Study Completion Date:	March 2015
Primary Completion Date:	April 2013 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Experimental: 1.0	Drug: Maraviroc 150mg, 300mg or 600mg twice daily x 144 weeks; dosing dependent on components of the current suppressive anti-HIV therapy Other Name: Selzentry, Celsentri
Placebo Comparator: 2	Drug: Placebo 150mg, 300mg or 600mg twice daily x 144 weeks; dosing dependent on components of the current suppressive anti-HIV therapy

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

HIV coinfected with HCV and/or HBV.
Undetectable HIV-1 RNA for at least 3 months prior to the screening visit
Treatment with current antiretroviral therapy (3-6 drugs excluding low-dose ritonavir) for at least 5 months.

Exclusion Criteria:

Currently receiving maraviroc.
Active opportunistic infections.
ALT and/or AST >5x upper limit of normal.
Direct bilirubin >1.5x upper limit of normal.
Severe or decompensated liver disease.
Liver disease unrelated to viral hepatitis infection.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT01327547

Hide Study Locations

Locations

United States, California
The Office of Dr. Franco Antonio Felizarta, M.D.
Bakersfield, California, United States, 93301
AIDS Research Alliance
Los Angeles, California, United States, 90015
Alameda County Medical Center
Oakland, California, United States, 94602
University of California Davis Research
Sacramento, California, United States, 95814
University of California
Sacramento, California, United States, 95817
UCSF - San Fancisco General Hospital
San Francisco, California, United States, 94110
United States, Florida
Community AIDS Resource Inc dba Care Resource
Miami, Florida, United States, 33137
University of South Florida Health - HIV Clinical Research Unit
Tampa, Florida, United States, 33602
Rowan Tree Medical, P.A.
Wilton Manors, Florida, United States, 33305
United States, Georgia
Medical College of Georgia
Augusta, Georgia, United States, 30912
United States, Iowa
University of Iowa Hospitals and Clinics
Iowa City, Iowa, United States, 52242
United States, Michigan
Henry Ford Hospital
Detroit, Michigan, United States, 48202
United States, New Jersey
Saint Michael's Medical Center
Newark, New Jersey, United States, 07102
United States, New York
Mount Sinai School of Medicine
New York, New York, United States, 10029
New York Medical College
Valhalla, New York, United States, 10595
United States, North Carolina
I.D. Consultants, P.A.
Charlotte, North Carolina, United States, 28209
United States, Oregon
Kaiser Permanente Sunnybrook Medical Office
Clackamas, Oregon, United States, 97015
Kaiser Permanente Northwest
Portland, Oregon, United States, 97227
United States, Texas
Southwest Infectious Disease Clinical Resesarch
Dallas, Texas, United States, 75001
University of Texas Southwestern Medical Center at Dallas
Dallas, Texas, United States, 75235
University Health Care Center Downtown
San Antonio, Texas, United States, 78207
Czech Republic
Fakultni nemocnice Brno
Brno, Czech Republic, 625 00
France
Hopital de la Croix Rousse
Lyon cedex 4, France, 69317
Hopital Tenon, Service des Maladies Infectieuses
Paris, France, 75020
Centre Hospitalier Cochin Saint Vincent de Paul
Paris CEDEX 14, France, 75679
Germany
EPIMED - Gesellschaft fuer epidemiologische und klinische Forschung in der Medizin mbH
Berlin, Germany, 12157
Universitaetsklinikum Bonn, Immunologische Ambulanz HIV
Bonn, Germany, 53127
Universitaetsklinikum Hamburg-Eppendorf
Hamburg, Germany, 20246
ifi - Studien und Projekte GmbH
Hamburg, Germany, 20099
Klinikum der Universitaet zu Koeln, Klinik I fuer Innere Medizin
Koeln, Germany, 50937
Ludwig-Maximilians-Universitaet, Medizinische Poliklinik - Klinikum Innenstadt
Muenchen, Germany, 80336
Hungary
Egyesitett Szent Istvan es Szent Laszlo Korhaz-Rendelointezet / V. Fertozo Belgyogyaszati Osztaly
Budapest, Hungary, 1097
Poland
Wojewodzki Szpital Obserwacyjno - Zakazny im. Tadeusza Browicza w Bydgoszczy
Bydgoszcz, Poland, 85-030
SPZOZ Wojewodzki Szpital Zakazny
Warszawa, Poland, 01-201
EMC Instytut Medyczny S.A. Przychodnia przy ul. Lowieckiej
Wroclaw, Poland, 50-220
Puerto Rico
Ararat Research Center
Ponce, Puerto Rico, 00717
University of Puerto Rico - School of Medicine
San Juan, Puerto Rico, 00935
Spain
Hospital Universitari Vall d�Hebron
Barcelona, Spain, 08035
Hospital Reina Sofia � Hospital Provincial
Cordoba, Spain, 14004
Hospital Carlos Iii
Madrid, Spain, 28029
Hospital Nuestra Se� de Valme
Sevilla, Spain, 41014
Consorcio Hospital General Universitario de Valencia
Valencia, Spain, 46014
United Kingdom
St Stephen's AIDS Trust
London, United Kingdom, SW10 9NH
Harrison Wing Research Office, Guys and St. Thomas� NHS Foundation Trust
London, United Kingdom, SE1 7EH

Sponsors and Collaborators

ViiV Healthcare

Pfizer

Investigators

Study Director:

Pfizer CT.gov Call Center

Pfizer

More Information

Additional Information:

To obtain contact information for a study center near you, click here. This link exits the ClinicalTrials.gov site

No publications provided

Responsible Party:	ViiV Healthcare
ClinicalTrials.gov Identifier:	NCT01327547 History of Changes
Other Study ID Numbers:	A4001098
Study First Received:	March 22, 2011
Last Updated:	May 7, 2013
Health Authority:	United States: Food and Drug Administration

Keywords provided by ViiV Healthcare:

HIV coinfection
maraviroc
CCR5 blocker

entry inhibitor
liver disease
viral hepatitis

Additional relevant MeSH terms:

Hepatitis
Hepatitis A
Hepatitis B
Hepatitis C
Liver Diseases
Digestive System Diseases
Hepatitis, Viral, Human
Virus Diseases
Enterovirus Infections
Picornaviridae Infections

RNA Virus Infections
Hepadnaviridae Infections
DNA Virus Infections
Flaviviridae Infections
Anti-Retroviral Agents
Antiviral Agents
Anti-Infective Agents
Therapeutic Uses
Pharmacologic Actions

ClinicalTrials.gov processed this record on May 22, 2013